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Abstract
Epigenetic gene silencing by histone modifications and DNA methylation is essential for cancer development. The
molecular mechanism that promotes selective epigenetic changes during tumorigenesis is not understood. We report here
that the PIAS1 SUMO ligase is involved in the progression of breast tumorigenesis. Elevated PIAS1 expression was observed
in breast tumor samples. PIAS1 knockdown in breast cancer cells reduced the subpopulation of tumor-initiating cells, and
inhibited breast tumor growth in vivo. PIAS1 acts by delineating histone modifications and DNA methylation to silence the
expression of a subset of clinically relevant genes, including breast cancer DNA methylation signature genes such as cyclin
D2 and estrogen receptor, and breast tumor suppressor WNT5A. Our studies identify a novel epigenetic mechanism that
regulates breast tumorigenesis through selective gene silencing.
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Introduction
Both genetic and epigenetic alterations contribute to cancer
development [1–3]. Tumor suppressors and epigenetic gatekeeper
genes are frequently silenced by epigenetic mechanisms during
tumor initiation and progression [3–5]. Extensive studies have
been performed in the identification and characterization of
altered DNA methylation in breast cancer development and
progression. More than 100 genes have been reported to be
aberrantly hypermethylated in breast tumors or breast cancer cell
lines [1,6]. Many of these genes play important roles in the
regulation of cell cycle, apoptosis, angiogenesis, metastasis and
tumor initiation. It has been proposed that breast cancer-specific
DNA methylation signatures can extend our ability to classify
breast cancer and predict outcome beyond what is currently
possible [6]. Epigenetic therapy holds a promising potential for the
successful treatment of cancer since epigenetic changes are
reversible as opposed to mutations [7]. The approval of DNA
methylation and histone deacetylase (HDAC) inhibitors for cancer
treatment offers new promise for epigenetic therapy. However,
these drugs are rather nonspecific, and the development of more
effective strategies for epigenetic therapy requires a thorough
understanding of the molecular specificity involved in epigenetic
gene silencing.
Most tumors are composed of a mixture of cancer cells, and the
heterogeneity of tumors is the major obstacle to effective cancer
therapy. It has been demonstrated that a sub-population of cancer
cells, referred to as tumor-initiating cells (TICs) or cancer stem
cells, is tumorigenic when transplanted into immunosuppressed
nonobese diabetic/severe combined immunodeficiency (NOD/
SCID) mice [8]. TICs display some key properties of stem cells
including self-renewal and multilineage differentiation [9]. In
addition, TICs are found to be resistant to radiation and
conventional chemotherapies [10–13]. Therefore, TICs may
largely contribute to tumor cellular heterogeneity, tumor progres-
sion and tumor recurrence [14–17].
PIAS1 is a member of the PIAS (protein inhibitor of activated
STAT) transcriptional regulator family that possesses SUMO
(small ubiquitin-like modifier) E3 ligase activity [18]. Biochemical
and genetic studies indicate that PIAS1 is a physiologically
important transcriptional repressor of STAT1 and NF-kappaB
[19–21]. PIAS1 is rapidly activated by phosphorylation on Ser90
residue in response to a variety of stimuli, including pro-
inflammatory signals, TCR activation and growth factors.
Activated PIAS1 is then recruited to gene promoters to repress
transcription [22,23]. Recent studies indicate that PIAS1 mediates
a novel epigenetic regulatory mechanism to control natural
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regulatory T cell (Treg) differentiation. PIAS1 binds to the Foxp3
promoter to maintain a repressive chromatin state through the
recruitment of DNA methyltransferases (DNMTs) and HP1-
gamma [24]. These findings indicate that this newly identified
PIAS1 epigenetic mechanism plays an important role in T cell
differentiation.
In this paper, we report that PIAS1 is important for breast
tumorigenesis. Elevated PIAS1 expression was observed in breast
cancer patient samples. PIAS1 knockdown in breast cancer cells
inhibited tumor growth in vivo. Most interestingly, mechanistic
studies indicate that PIAS1 suppresses a number of- genes
clinically relevant to breast tumorigenesis through epigenetic
mechanisms. These studies suggest that targeting the PIAS1
epigenetic signaling pathway may represent a novel therapeutic
strategy for cancer treatment.
Results
Elevated PIAS1 expression in primary human breast
cancer tissues
To test whether PIAS1 is involved in breast cancer progression,
immunohistochemistry (IHC) tissue arrays were performed to
examine the expression of PIAS1 protein in a panel of primary
human breast tumor samples. PIAS1 is a nuclear protein, but it
diffused to the cytoplasm under formalin fixation conditions
(Figure S1 in File S1), a phenomenon observed with other nuclear
proteins [25]. IHC analyses indicate that PIAS1 is significantly
upregulated in primary breast cancer samples at early stages of
breast ductal carcinoma in situ (DCIS) as well as invasive ductal
carcinoma (IDC) (Fig. 1a).
PIAS1 is important for breast tumorigenesis
To directly test whether PIAS1 plays a functional role in breast
tumorigenesis, RNA interference approach was used to knock-
down the expression of PIAS1 protein in MDA-MB231 cells.
Stable cell lines expressing a scramble short hairpin RNA (control
shRNA) or two independent PIAS1 shRNAs (shRNA1 and
shRNA2) were obtained. Western blot analysis showed that
PIAS1 expression was significantly suppressed by both PIAS1
shRNAs, although a more efficient inhibition by PIAS1 shRNA2
was observed (Fig. 1b). PIAS1 knockdown did not affect the
growth of MDA-MB231 cells under the conventional serum-
containing conditions (DMEM) (Fig. 1c, left panel). In contrast,
when these cells were cultured under serum-free growth factor-
enriched conditions (Stem Cell Media; SCM), which favor normal
stem cells and more closely resemble primary tumors than the
DMEM condition [26], PIAS1 knockdown significantly inhibited
the survival of MDA-MB231 cells (Fig. 1c, right panel). To directly
test the effect of PIAS1 knockdown on tumor growth in vivo,
xenograft experiments were performed in SCID mice. PIAS1
knockdown significantly inhibited the tumor formation of MDA-
MB231 cells in both the subcutaneous and the fat pad models
(Fig. 1d), suggesting an important role of PIAS1 in the regulation
of breast tumorigenesis.
PIAS1 regulates the self-renewal of breast tumor
initiating cells (TICs)
The finding that PIAS1 knockdown affects breast cancer cell
survival specifically under the conditions that favor stem cell
growth suggests a possibility that PIAS1 may play a role in the
regulation of breast cancer stem cells/tumor-initiating cells (TICs).
Previous studies suggest that the ALDH+ subpopulation of breast
cancer cells is highly enriched in breast TICs [27]. ALDEFLUOR
assays revealed that PIAS1 knockdown almost completely
eliminated the ALDH+ population (Fig. 2a), supporting the
hypothesis that PIAS1 knockdown inhibits breast TICs. To
further test whether PIAS1 regulates breast TICs, the control
and PIAS1 knockdown MDA-MB231 cells were subjected to
mammosphere assays [14,28,29]. PIAS1 knockdown significantly
inhibited the formation of mammospheres (Fig. 2b), suggesting
that PIAS1 regulates the self-renewal of breast TICs.
PIAS1 Ser90 phosphorylation and SUMO ligase activity
are required for PIAS1-mediated regulation of breast TICs
Previous studies indicate that PIAS1 is activated by Ser90
phosphorylation to bind to chromatin and repress transcription of
target genes in response to pro-inflammatory stimuli [22], a
process that is dependent on the SUMO ligase activity of PIAS1.
We explored whether PIAS1 can also be activated by growth
factor signals. Western blot analysis revealed that PIAS1 became
phosphorylated on Ser90 in response to EGF or Heregulin in
various breast cancer cell lines, including MDA-MB231, BT-20,
BT-474 and HCC-1954 (Fig. 2c). To test the importance of PIAS1
Ser90 phosphorylation and PIAS1 SUMO ligase activity in the
regulation of breast TICs, PIAS1 shRNA1 knockdown MDA-
MB231 cells were rescued with either an empty vector (Vec), wild
type PIAS1 (WT), PIAS1 Ser90 mutant (S90A), or PIAS1 SUMO
ligase defective mutant (W372A) through an shRNA escape
approach, in which silent mutations were introduced into PIAS1
expression constructs to escape the inhibitory effect of PIAS1
shRNA. Western blot analysis indicated that the expression of WT
or mutant PIAS1 proteins in the rescued cell lines was comparable
to that of the MDA-MB231 control cells (Fig. 2d).
Consistent with the previous results (Fig. 1c), the introduction of
either WT or S90A and W372A PIAS1 mutants did not affect cell
growth under the conventional DMEM conditions (Fig. 2e, left
panel). In contrast, when these cells were cultured under SCM
conditions, only WT, but not the vector (Vec) or W372A mutant
PIAS1 reconstituted cells, rescued cells from cell death (Fig. 2e,
right panel). PIAS1 S90A mutant showed minor increase in cell
survival, although the increase is not statistically significant (Fig. 2e,
right panel). In addition, mammosphere assays were performed to
examine the ability of WT or PIAS1 mutants to support the self-
renewal of TICs. The introduction of PIAS1 WT into PIAS1
knockdown cells promoted the formation of mammospheres
(Fig. 2f). The introduction of PIAS1 S90 or W372 mutant resulted
in minor increases in mammospheres, although the increases are
not statistically significant (Fig. 2f). Consistently, ALDEFLUOR
assays indicated that PIAS1 WT, but not S90 or W372 mutant,
restored the population of ALDH+ TICs (Fig. 2g). Taken together,
these studies suggest that the observed inhibition of TICs in PIAS1
knockdown cells is due to the reduction of PIAS1 expression, and
that both PIAS1 Ser90 phosphorylation and SUMO ligase activity
are required for the maintenance of the breast TICs.
PIAS1 selectively represses a subset of genes clinically
relevant to breast cancer
We explored the molecular mechanism of PIAS1-mediated
regulation of breast TICs. Gene profiling studies were performed
to identify PIAS1 downstream genes involved in tumorigenesis.
Total RNAs from the control and PIAS1 knockdown MDA-
MB231 cells cultured under DMEM or SCM conditions were
subjected to microarray analysis. Since PIAS1 is a transcriptional
repressor and PIAS1 knockdown inhibited self-renewal of breast
TICs under SCM conditions, we focused on the genes that were
preferentially upregulated in PIAS1 knockdown cells under SCM
conditions (Table S1 in File S1). Interestingly, among the group of
PIAS1 Epigenetic Pathway in Breast Cancer
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Figure 1. PIAS1 is important for tumorigenesis of breast cancer. (a) PIAS1 protein levels are increased in breast tumor samples as revealed by
tissue microarray analysis. Left panel: Representative tissue microarray spot from morphologically normal duct, ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma (IDC). Right panel: a box and whisker plot of PIAS1 levels in various tissue samples. Total sample numbers (n) were
indicated. P values are determined by non-parametric two-tailed Kruskal Wallis test with alpha level equals 0.05. ‘‘+’’, the mean of each population;
‘‘D’’, outliers. (b) Western blot analyses were performed with whole cell extracts from MDA-MB231 cells containing a control shRNA or two
independent PIAS1 shRNAs (PIAS1 shRNA1 and 2). (c) The growth of MDA-MB231 control shRNA, PIAS1 shRNA1 and shRNA2 cells in DMEM
supplemented with 10% FBS (left), or Stem Cell Media (SCM) (right) (mean 6 SEM). Shown is a representative of 3 independent experiments. P values
were determined by paired t-test. (d) In vivo tumorigenesis studies. MDA-MB231 cells containing a control shRNA or PIAS1 shRNA2 were injected into
the female SCID-beige mice subcutaneously (left: 16106 cells/mouse; n = 4), or in fat pad (right: 26105 cells/mouse; n = 5). Shown is a representative
of 3 independent experiments. Each data point represents mean 6 SEM. P values were determined by non-paired t-test.
doi:10.1371/journal.pone.0089464.g001
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genes strongly induced by PIAS1 knockdown, several genes are
known to be clinically relevant to breast cancer, including breast
cancer DNA methylation signature genes Cyclin D2 (CCND2) and
Estrogen receptor (ESR1), candidate tumor suppressor WNT5A,
progestagen-associated endometrial protein (PAEP), as well as
leucine zipper, downregulated in cancer 1 (LDOC1). WNT5A,
which signals through a non-canonical WNT pathway, is a
candidate tumor suppressor in breast cancers [30]. The loss of
WNT5A is associated with early relapse in invasive ductal breast
carcinomas (IDC) and short recurrence-free survival. PAEP (also
known as GDA/PP14) is an epithelial differentiation-related gene.
PAEP expression is associated with a more favorable prognosis in
breast and ovarian cancers, and PAEP inhibits breast tumor
growth in SCID mice [31,32]. CCND2 is frequently silenced in a
variety of human cancers, including breast and ovarian cancers,
through promoter hypermethylation [33,34]. LDOC1 has been
reported to be downregulated in pancreatic and gastric cancer
cells [35].
The induction of these genes identified by microarray was
validated by quantitative real time PCR (Q-PCR) analysis in two
independent PIAS1 knockdown MDA-MB231 cell lines (Fig. 3a
and Table S2 in File S1). As a control, PIAS1 knockdown did not
show significant effect on the expression of WNT1 and CCND1,
which show sequence homologies, but are functionally distinct in
tumorigenesis, from WNT5A and CCND2, respectively. These
results suggest that PIAS1 shows specificity in gene repression.
Consistently, the transcription of WNT5A and CCND2, but not
CCND1, was also elevated in PIAS1 knockdown xenograft tumor
samples (Fig. 3b).
PIAS1 promotes self-renewal of breast TICs through
WNT5A suppression
The WNT pathway is known to play a role in the regulation of
self-renewal of stem cells [36-38]. Consistent with the gene
expression results, higher levels of WNT5A protein were detected
in PIAS1 knockdown MDA-MB231 cells (Fig. 4a). WNT5A
shRNA was introduced into PIAS1 shRNA2 knockdown MDA-
MB231 cells to inhibit WNT5A expression. While WNT5A
shRNA1 efficiently inhibited the expression of WNT5A, WNT5A
shRNA2 showed only a minor inhibition of WNT5A expression
(Fig. 4b). Mammosphere assays showed that the suppression of
WNT5A expression by WNT5A shRNA1 significantly enhanced
the formation of mammospheres (Fig. 4c). Furthermore, the
exogenous administration of recombinant WNT5A protein
efficiently inhibited the mammosphere formation of parental
MDA-MB231 cells (Fig. 4d). Consistently, the knockdown of
WNT5A by shRNA1 significantly enhanced the tumor growth of
PIAS1 knockdown MDA-MB231 cells in vivo (Fig. 4e). These
studies support a role of WNT5A in PIAS1 knockdown-mediated
inhibition of the self-renewal of breast TICs and breast tumori-
genesis.
PIAS1 promotes epigenetic gene silencing in breast
cancer cells
Our recent studies showed that PIAS1 restricts nTreg differen-
tiation by recruiting DNMTs to the Foxp3 promoter to promote
DNA methylation and epigenetic silencing [24]. We explored
whether the PIAS1 epigenetic pathway also operates in breast
cancer cells. Our previous results showed that PIAS1 inhibits the
expression of CCND2, ESR1 and WNT5A; but not CCND1 (Fig. 3).
Hypermethylation of the CCND2, ESR1 andWNT5A loci has been
reported in various cancer types [39–42]. Therefore, chromatin
immunoprecipitation (ChIP) assays were performed to test
whether PIAS1 was associated with the genomic loci with close
proximity to the reported methylation regions of the CCND2,
ESR1 and WNT5A genes in MDA-MB231 cells. As shown in
Fig. 5a, PIAS1 bound to the CCND2, ESR1 andWNT5A loci in the
control shRNA cells, while the binding was reduced in PIAS1
shRNA2 cells. Furthermore, PIAS1 was not associated with the
CCND1 promoter (Fig. 5a), consistent with the finding that PIAS1
does not affect the expression of CCND1 (Fig. 3). Interestingly,
PIAS1 knockdown resulted in a substantial increase of the active
histone mark histone H3 acetylation (AcH3) on the WNT5A gene
(Fig. 5b). In contrast, the repressive modifications, such as histone
H3 K27 trimethylation (H3K27me3) and histone H3 K9
trimethylation (H3K9me3), were considerably reduced in PIAS1
knockdown cells (Fig. 5b). Similar changes in AcH3 and
H3K9me3 were observed in the CCND2 promoter (Fig. 5c). As a
control, H3K9me3 was readily detectable in the centromeric
satellite repeat, Satellite 2, a heterochromatin region [43] in MDA-
MB231 cells (Fig. 5d). More importantly, the H3K9me3 level was
not affected in PIAS1 knockdown cells, suggesting that PIAS1 does
not affect global heterochromatin structure (Fig. 5d). In addition,
while H3K9me3 and H3K27me3 were not detectable in the
CCND1 promoter, the AcH3 level was not affected by PIAS1
knockdown (Fig. 5e), consistent with the finding that PIAS1 does
not affect the CCND1 expression (Fig. 3). Taken together, these
results suggest that PIAS1 regulates histone modifications of its
target genes.
CCND2 and ESR1 are signature genes that are frequently
methylated in breast cancer [1]. Bisulfite sequencing analysis
indicated that the promoter of CCND2 was methylated in MDA-
MB231 control cells, which was significantly reduced in PIAS1
knockdown cells (Fig. 6a). Similar reductions in DNA methylation
were observed in ESR1 and WNT5A genes (Fig. 6a). Consistently,
ChIP assays indicated that both DNMT1 and DNMT3A bind to
Figure 2. PIAS1 is important for the maintenance of the Tumor Initiating Cells (TICs) in MDA-MB231 cells. (a) Reduced ALDH+
population in PIAS1 knockdown cells using the ALDEFLUOR assay. Cells cultured in Stem Cell Media (SCM) for 25 days were incubated with
ALDEFLUOR substrate (BAAA) with or without the specific inhibitor of ALDH, DEAB, to define the ALDH+ population (R2). The number indicates the
percentage of the ALDH+ population. (b) Mammosphere assays. MDA-MB231 control shRNA and PIAS1 shRNA1 and shRNA2 cells were seeded in SCM
on 35 mm petri dishes (5,000 cells/dish) and spheres were counted 7 days later. (c) PIAS1 is phosphorylated on Ser90 in response to EGF and
Heregulin in breast cancer cells. Various breast cancer cells were starved for 16 h, then either untreated or treated with EGF (100 ng/ml) or Heregulin
(15 ng/ml) for indicated time points. Western blot analyses were performed with whole cell extracts, using an antibody specific for Ser90-
phosphorylated PIAS1 (anti-pPIAS1) or total PIAS1 (anti-PIAS1). (d) Reconstitution of MDA-MB231 PIAS1 shRNA1 cells with the lenti-viruses encoding
the empty vector (Vec), wild type PIAS1 (WT), PIAS1 S90A mutant (S90A), or PIAS1 W372A mutant (W372A). Western blot was performed with whole
cell extracts from these cells using anti-PIAS1 or anti-Tubulin. (e) The effect of WT or S90A and W372A PIAS1 mutants on cell proliferation and
survival. MDA-MB231 cells as in d were seeded in DMEM supplemented with 10% FBS (left), or Stem Cell Media (SCM) (right) (mean6 SEM). Shown is
a representative of 3 independent experiments. P values were determined by paired t-test. (f) Mammosphere assay. MDA-MB231 cells as in d were
seeded in SCM at 5,000 cells/dish. Spheres were counted 7 days after plating. (g) ALDEFLUOR assay. MDA-MB231 cells as in d were cultured in SCM
for 5 days, and the ALDH+ population was determined by the ALDEFLUOR assays. Shown in each panel is a representative of 3 independent
experiments. Error bars represent SEM. P values were determined by paired t-test.
doi:10.1371/journal.pone.0089464.g002
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the CCND2 promoter in the control MDA-MB231 cells, while the
binding was compromised by PIAS1 knockdown (Fig. 6b). These
studies suggest that PIAS1 recruits DNMTs to promote DNA
methylation in breast cancer cells.
Discussion
Although extensive studies have been performed in the
identification and characterization of altered DNA methylation
and epigenetic modifications in breast cancer development and
progression [1,4–6], the molecular mechanism involved in this
process has not been understood. Studies described in this
manuscript have identified a novel epigenetic control mechanism
in promoting selective epigenetic silencing in breast cancer. Our
results suggest that the PIAS1 epigenetic pathway, which has been
previously shown to function in regulatory T cell differentiation
[24], is up-regulated in breast cancer and is involved in promoting
DNA methylation and epigenetic silencing of breast cancer
signature genes such as ESR1 and CCND2, as well as the breast
tumor suppressor WNT5A.
Microarray analysis of PIAS1 knockdown breast cancer cells has
uncovered an essential role of PIAS1 in the suppression of a group
of genes previously known to be clinically relevant to breast
cancer, such as WNT5A (Fig. 3). The WNT family of proteins can
signal through the canonical beta-catenin-dependent or the non-
canonical beta-catenin-independent pathway [36–38]. WNT5A
belongs to the nontransforming class of the WNT gene family that
Figure 3. PIAS1 regulates the expression of a panel of tumor suppressor genes. (a) Real-time quantitative PCR (Q-PCR) assay. MDA-MB231
cells containing control shRNA, PIAS1 shRNA1 or shRNA2 were cultured in DMEM plus 10% FBS (DMEM) or Stem Cell Media (SCM) for 30 h, and total
RNA was used for Q-PCR assays with gene-specific primers. The gene names are labeled at the top left of each panel. The data were normalized by
beta-Actin (ACTB) and presented as ‘‘Relative Expression’’ as compared to that in control shRNA cells under DMEM condition, which was set as ‘‘1’’
except for the ESR1 gene (the expression was not detectable in control shRNA cells). Shown is a representative of 3 independent experiments. Error
bars represent SD. ND, not detected. See also Table S1 and Table S2 in File S1. (b) Same as in a except that total RNA from fat pad tumor xenograft
samples were used (n = 5). Error bars represent SEM. P values were determined by non-paired t-test.
doi:10.1371/journal.pone.0089464.g003
PIAS1 Epigenetic Pathway in Breast Cancer
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activates non-canonical signaling pathways. The biology of
WNT5A is cell-type dependent, and it has been reported that
WNT5A may signal through different WNT receptors to cause
different cellular responses [44]. Gene targeting studies indicate
that WNT5A is required for normal mammary gland develop-
ment, and Wnt5a-null ammary tissue shows an accelerated
developmental capacity [45]. In addition, WNT5A overexpression
inhibits tumorigenesis of uroepithelial cell carcinoma and
suppresses mammary cell migration [46,47]. The loss of WNT5A
is associated with early relapse in invasive ductal breast carcinomas
and short recurrence-free survival, supporting WNT5A as a
candidate breast tumor suppressor [30]. The tumor suppressor
function of WNT5A has also been suggested in other human
cancers [48,49]. In this report, we showed that PIAS1-mediated
regulation of the self-renewal of breast TICs is largely achieved
through the transcriptional repression of WNT5A. The exogenous
administration of recombinant WNT5A protein to MDA-MB231
breast cancer cells suppressed mammosphere. Consistently,
WNT5A inhibition by shRNA rescued PIAS1 knockdown-
mediated suppression of mammosphere and tumor growth in vivo
(Fig. 4). Our results suggest that the PIAS1-WNT5A pathway
regulates the self-renewal of breast TICs.
PIAS1 is a nuclear SUMO E3 ligase that functions as a
transcriptional repressor. PIAS1 is activated by Ser90 phosphor-
ylation in response to proinflammatory stimuli. Activated PIAS1 is
then recruited to gene promoters to repress transcription [22,50].
In this report, we showed that PIAS1 is also phosphorylated/
activated in response to growth stimuli, and the ability of PIAS1 to
regulate the self-renewal of breast TICs requires PIAS1 Ser90
phosphorylation as well as PIAS1 SUMO E3 ligase activity (Fig. 2).
Our studies suggest that PIAS1 may act as a sensor protein in the
nucleus that responds to growth and inflammatory stimuli in the
tumor microenvironment to regulate the self-renewal of TICs
through epigenetic gene regulation.
In conclusion, studies described in this paper suggest that PIAS1
plays an important role in promoting selective epigenetic silencing
during breast tumorigenesis. It is possible that the PIAS1
epigenetic pathway may provide a link between inflammation
and the development of breast cancer (Fig. 7). Targeting the
PIAS1 epigenetic pathway may represent a novel therapeutic
strategy for the treatment of breast cancer.
Figure 4. PIAS1-mediated WNT5A suppression is important for the maintenance of breast Tumor Initiating Cells (TICs). (a) Western
blot analyses with whole cell extracts from MDA-MB231 cells containing control shRNA, PIAS1 shRNA1 or shRNA2 cultured in DMEM plus 10% FBS. (b)
Western blot analyses with whole cell extracts from MDA-MB231 PIAS1 shRNA2 cells containing either a control shRNA, a WNT5A-specific shRNA
(WNT5A shRNA1), or a non-working WNT5A shRNA (WNT5A shRNA2). (c) Mammosphere assay. Cells were seeded in Stem Cell Media (SCM) at
5,000 cells/dish, and spheres were counted 7 days later. Shown is a representative of 3 independent experiments. Error bars represent SEM. P values
were determined by paired t-test. (d) Same as in c except that the parental MDA-MB231 cells were used with or without recombinant WNT5A
treatment as indicated. (e) Tumorigenesis in vivo. Cells as in b were injected subcutaneously into SCID-beige mice (56106 cells/mice; n = 6). Shown is
a representative of 3 independent experiments. Each data point represents mean 6 SEM. P values were determined by non-paired t-test.
doi:10.1371/journal.pone.0089464.g004
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Figure 5. PIAS regulates the histone marks of the target genes. (a) Chromatin immunoprecipitation (ChIP) assay. Extracts from MDA-MB231
cells containing control shRNA, or PIAS1 shRNA2 were immunoprecipitated with anti-PIAS1 or IgG. The bound DNA was quantified by Q-PCR with
gene-specific primers and presented as ‘‘percent of input’’ (% input). (b) Same as in a except that antibodies specific for acetylated histone H3 (AcH3),
histone H3 trimethylated at Lys9 (H3K9me3), or histone H3 trimethylated at Lys27 (H3K27me3) were used, and the levels of these histone marks at
the WNT5A loci were quantified. (c) Same as in b except that histone marks at the CCND2 promoter were quantified. (d) Same as in b except that the
level of H3K9me3 at the heterochromatin region Satellite 2 was quantified. (e) Same as in b except that histone marks at the CCND1 promoter were
quantified. Shown in each panel is a representative of 3 independent experiments. Error bars represent SD.
doi:10.1371/journal.pone.0089464.g005
PIAS1 Epigenetic Pathway in Breast Cancer
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Materials and Methods
Mice, cell Lines and reagents
Tissue samples from breast cancer patients used for IHC
analysis were purchased from commercial companies (Imgenex
and Full Moon Biosystems). The work is exempt from Human
Research since the data were analyzed anonymously. Human
breast cancer cell lines MDA-MB231, BT-20, BT-474 and HCC-
1954 were obtained from ATCC. MDA-MB231 cells were
maintained in DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% Penicillin/Streptomycin. All other cells were
maintained in RPMI supplemented with 10% FBS and 1%
Penicillin/Streptomycin. Stem Cell Media (SCM) is composed of
DMEM/F-12 (Cellgro) supplemented with 0.4% BSA, 1%
Penicillin/Streptomycin, 2 mM Glutamine, 25 ng/ml human
EGF (R&D), 25 ng/ml human basic FGF (R&D) and 5 ug/ml
human insulin (Sigma). The following agents have also been used:
Heregulin (Upstate), anti-pPIAS1 (Ser90-phosphorylated PIAS1)
[22], polyclonal anti-PIAS1 [20], [51]; anti-Tubulin (Sigma), anti-
WNT5A/B (Cell Signaling) and recombinant murine WNT5A
protein (R&D). This study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by The UCLA Institutional Animal Care
and Use Committee (Protocol Number: 1999-015-43A).
shRNA knockdown and reconstitution
Oligonucleotides encoding a control small hairpin RNA
(shRNA) or various shRNAs targeting PIAS1 or WNT5A were
cloned under the control of the U6 promoter in the Lentiviral
vector CS-CP for PIAS1 (containing a puromycin-resistant
marker) or CS-CH for WNT5A (containing a hygromycin-
resistant marker), which was modified from the CS-CG Lentiviral
vector [52]. Lentiviruses were generated by co-transfecting 293T
cells with shRNA constructs together with helper plasmids pCMV-
VSV-G and pHR’8.9DVPR using the calcium phosphate method.
The viral supernatant was collected 72 h post transfection, and
used to infect various cancer cells. Cells were subjected to drug
selection (puromycin: 2.5 ug/ml; hygromycin: 250 ug/ml) 48 h
post infection. The target sequences of the shRNAs are: Control
shRNA: GCACTACTGTCGATGACGA; PIAS1 shRNA1:
GTTTCTGATAAACAAAACC; PIAS1 shRNA2: GAAAC-
TATTCCATGGCAGT; WNT5A shRNA1: AGTG-
CAATGTCTTCCAAGT; WNT5A shRNA2: TATTAAGCC-
CAGGAGTTGC.
The wild type (WT), S90A and W372A mutant PIAS1 escape
expression constructs were generated by insertion of WT or
mutant PIAS1 cDNA fragments into the Lentiviral expression
vector bearing a Hygromycin-resistant marker. These PIAS1
cDNAs carried 4 silent mutations that can escape the inhibition by
shRNA without changing the codons of the protein (only the third
nucleotide of each codon was altered). Lentiviruses were obtained
as described above and target cells were infected with viral
supernatant followed by Hygromycin selection.
In vitro mammosphere formation. In vitro mammosphere
assays with MDA-MB231 cells were performed as described
[12,27]. Briefly, cells were seeded under SCM conditions at
indicated densities on 35 mm petri dish. Fresh human EGF
(25 ng/ml), basic FGF (25 ng/ml) and Insulin (5 ug/ml) were
supplemented every 2 days. Spheres were counted under a
microscope after 5–7 days of culture.
Figure 6. PIAS1 regulates DNA methylation status of the target genes. (a) DNA Methylation analyses of the indicated loci were performed
by bisulfite conversion of genomic DNA from MDA-MB231 cells containing control shRNA or PIAS1 shRNA2. The x axis represents the positions of the
CpG sites relative to the transcription start site (+1); the y axis represents the percentage. (b) Chromatin immunoprecipitation (ChIP) assay. Extracts
from MDA-MB231 cells containing control shRNA, or PIAS1 shRNA2 were immunoprecipitated with anti-DNMT1, anti-DNMT3A or IgG. The bound
DNA was quantified by Q-PCR with CCND2 promoter-specific primers and presented as ‘‘percent of input’’ (% input). Shown in each panel is a
representative of 3 independent experiments. Error bars represent SD.
doi:10.1371/journal.pone.0089464.g006
Figure 7. A proposed model of the function of PIAS1 in breast cancer. In response to growth factor and inflammatory signals, PIAS1 is
activated via Ser90 phosphorylation (S90p), and recruited to the target gene promoters. PIAS1 represses the expression of epigenetic gatekeeper
genes, such as ESR1, WNT5A and CCND2, by promoting inhibitory histone H3 lysine 9 and lysine 27 trimethylation (H3K9/K27) and DNA methylation
(Met), while inhibiting acetylated histone H3 (AcH3). Therefore, PIAS1 promotes tumorigenesis by selective epigenetic gene silencing.
doi:10.1371/journal.pone.0089464.g007
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Cell proliferation assay
For MDA-MB231 cell proliferation under DMEM conditions,
cells were seeded in DMEM plus 10% FBS and 1% Penicillin/
Streptomycin at a density of 16105 cells per well in 6 well plate,
and stained with trypan blue and counted for viable cells everyday
for 5 days. Alternatively, cells were seeded at a density of 3,000
cells per well in 96 well tissue culture plate (08-772-3; Fisher), and
cell growth was determined everyday for 4–5 days by CellTiter96
AQueous One Solution Cell Proliferation Assay as instructed by
the manufacturer (Promega). For cell growth under SCM
conditions, cells were seeded in SCM at a density of 3,000 cells
per well in 96 well non-treated microplate (12-565-226; Fisher),
and supplemented with fresh human EGF (25 ng/ml), basic FGF
(25 ng/ml) and Insulin (5 ug/ml) every 2 days. Cell growth was
determined at indicated time points by CellTiter96 AQueous One
Solution Cell Proliferation Assay as instructed by the manufacturer
(Promega). Triplicates were performed for each time point of the
growth curve.
ALDEFLUOR assay
The ALDH+ cell population was determined using an
ALDEFLUOR assay kit as instructed (StemCell Technologies).
Briefly, cells grown under SCM condition were incubated with the
ALDH substrate BAAA in ALDEFLUOR assay buffer in the
presence or absence of the specific ALDH inhibitor diethylami-
nobenzaldehyde (DEAB) at 37uC for 45 min, followed by flow
cytometry. The ALDH+ population of each sample was deter-
mined using its own negative control (DEAB containing sample) as
a reference.
In vivo tumorigenesis
Exponentially growing cells were trypsinized and resuspended
in serum free-DMEM or RPMI, mixed with equal volume of
Matrigel (BD Biosciences), and injected into the fat pad, or
subcutaneously into the flank of 6–10 week old SCID beige mice
(UCLA Department of Radiation Oncology) in a volume of 150 ul
per site. Tumors were measured weekly with a caliper and tumor
volume was calculated as width x length x height x 0.526.
Tissue microarray analysis
Tissue microarray slides were obtained from Imgenex and Full
Moon Biosystems, and immunohistochemistry (IHC) staining was
performed using polyclonal anti-PIAS1 [20] as instructed by the
manufacturers. ‘‘Normal duct’’ was defined as normal breast
tissues from healthy individuals as well as histologically normal
tissues adjacent to tumors. Semiquantitative assessment of PIAS1
staining was performed using a 0–2 scale (0 = negative; 1 =weak
staining; 2 = strong staining) based on the average intensity per
epithelial cell, and PIAS1 score was defined as the product of
PIAS1 staining scale and the percentage of PIAS1 positive
staining. A total of 3 independent tissue arrays containing 30–
100 samples each were performed and the data were pooled.
Statistic analysis was performed using non-parametric two-tailed
Kruskal Wallis test with alpha level equals 0.05 for all tests, since
both ‘‘Normal duct’’ and ‘‘IDC’’ populations are not normally
distributed.
Microarray analysis
MDA-MB231 cells containing a control shRNA or PIAS1
shRNA2 were cultured in DMEM plus 10% FBS (DMEM) or
SCM for 30 h. Total RNA was prepared and subjected to
microarray analyses using the human genome U133A 2.0 array
chip (Affymetrix) as described [19]. The microarray data is
presented in Table S1 in File S1 and has been deposited to Gene
Expression Omnibus (GEO) database (GSE44024).
Quantitative real time PCR (Q-PCR)
Quantitative real time PCR (Q-PCR) analyses were performed
with breast cancer cells or tumor xenograft samples as described
previously [19]. Briefly, total RNA was prepared using RNA
STAT60 (Tel-Test). First strand complementary DNA was
produced by reverse transcription (RT) of 1 ug total RNA using
iScript cDNA synthesis kit (Bio-Rad). Q-PCR was carried out
using the CFX96 real-time PCR detection system (Bio-Rad) in a
final volume of 25 ul containing Taq polymerase, 1xTaq buffer,
125 uM dNTP, SYBR Green I (Molecular Probes) and gene-
specific primers. Amplification conditions were: 95uC (3 min), 40
cycles of 95uC (10 s) and 61uC (30 s). Q-PCR data were analyzed
by CFX Manager 2.0 software (Bio-Rad), and normalized by beta-
Actin (ACTB). The results were presented as ‘‘Relative Expression’’
as compared to that in the control shRNA cells, which was set as
‘‘1’’. Primers are listed in Table S2 in File S1.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the ChIP analysis kit as
instructed (Upstate). Briefly, cells grown in DMEM plus 10% FBS
were cross-linked and lysed. Chromatin was sheared by sonication
(10 s at 30% of the maximum strength for a total of six times). Cell
extracts were immunoprecipitated with indicated antibodies, or
IgG as a negative control. The binding of these factors to various
DNA regions was quantified by quantitative real time PCR (Q-
PCR) using the immunoprecipitates as templates and specific
primers (Table S2 in File S1). The results were presented as
‘‘percent of input’’. The following antibodies were used in the
ChIP assay: normal rabbit IgG (sc-2027; Santa Cruz), anti-PIAS1
[51], anti-histone H3 trimethylated at Lys9 (H3K9me3) (17-625;
Millipore); anti-histone H3 trimethylated at Lys27 (H3K27me3)
(17-622; Millipore); anti-Acetylated histone H3 (AcH3) (17-615;
Millipore); anti-DNMT1 (Ab13537; Abcam) and anti-DNMT3A
(R0015-2; Abiocode).
Bisulfite treatment and methylation analysis
Bisulfite modification of DNA was performed using EZ
Methylation-Gold kit (Zymo Research). Bisulfite genomic se-
quencing (BGS) was conducted using cells grown in DMEM plus
10% FBS as described [39–42]. Taq DNA polymerase (Zymo
Research) was used for PCR amplification using specific primers
(Table S2 in File S1). The PCR conditions were as follows: 1 cycle
of 95uC for 10 min, then 40 cycles of 95uC for 45 s, 56uC for
1 min, and 72uC for 1 min; and 1 cycle of 72uC for 10 min.
Amplified products were cloned into pCR4-Topo (Invitrogen),
with 8 to 12 colonies randomly chosen and sequenced.
Supporting Information
File S1 Contains the following files: Figure S1, Table S1 and
Table S2. Figure S1. Validation of the polyclonal anti-PIAS1
antibody by immunofluorescence. MDA-MB231 cells containing
control shRNA or PIAS1 shRNA2 were fixed by 3 different
methods as indicated, followed by staining with polyclonal anti-
PIAS1. FMA, formaldehyde. Table S1.Microarray analysis. Fold
induction is defined as the ratio of the expression levels of a given
gene in PIAS1 shRNA2 vs. control shRNA cells. Genes with
greater than 10-fold induction under Stem Cell Media (SCM)
condition are shown. Table S2. Primers used for Q-PCR, ChIP
and methylation.
(DOC)
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